Core Insights - China Resources Pharmaceutical (03320.HK) reported that Tianjin Tasly Pharmaceutical achieved total revenue of RMB 6.311 billion for the nine months ending September 30, 2025, a year-on-year decrease of 2.35% [1] - The net profit for Tianjin Tasly Pharmaceutical was RMB 999 million, reflecting a year-on-year increase of 19.85% [1] - As of the end of the reporting period, the cash and cash equivalents balance stood at RMB 1.183 billion [1] Group 1 - Tianjin Tasly Pharmaceutical's total revenue decreased by 2.35% year-on-year to RMB 6.311 billion [1] - The net profit increased by 19.85% year-on-year to RMB 999 million [1] - The cash and cash equivalents at the end of the period were RMB 1.183 billion [1] Group 2 - China Resources Pharmaceutical holds approximately 28% equity in Tianjin Tasly Pharmaceutical through its non-wholly owned subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. [1] - The shares of Tianjin Tasly Pharmaceutical are listed on the Shanghai Stock Exchange [1]

Core Viewpoint - China Resources Pharmaceutical (03320) reported Tianjin Tasly Pharmaceutical (600535) unaudited financial performance for the nine months ending September 30, 2025, showing a decline in total revenue but an increase in net profit [1] Financial Performance Summary - Total revenue for the period was approximately 6.311 billion yuan, representing a year-on-year decrease of 2.35% [1] - Net profit for the same period was approximately 992.5 million yuan, reflecting a year-on-year increase of 19.85% [1]

智通财经APP讯，华润医药(03320)公布天士力医药截至2025年9月30日止九个月的未经审核财务业绩， 营业总收入约63.11亿元，同比减少2.35%;净利润约9.925亿元，同比增长19.85%。 ...

证券代码：600535 证券简称：天士力 编号：临 2025-070 号 一、报告期内分行业经营数据 二、报告期内分治疗领域经营数据 单位：元 币种：人民币 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号—行业信 息披露》及《关于做好主板上市公司 2025 年三季度报告披露工作的重要提醒》的 要求，现将公司 2025 年前三季度主要经营数据披露如下： | 分治疗领域 | 营业收入 | 营业成本 | 毛利率 （%） | 营业收入比 上年增减 | 营业成本比 上年增减 | 毛利率比 上年增减 | | --- | --- | --- | --- | --- | --- | --- | | | | | | （%） | （%） | （%） | | 心血管及代谢 | 3,186,385,371.50 | 714,635,379.65 | 77.57 | 1.16 | 6.43 | -1.11 | | 神经/精神 | 1,085,227,997.38 | 548,643 ...

证券代码：600535 证券简称：天士力 编号：临 2025-069 号 天士力医药集团股份有限公司 第九届董事会第 15 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）第九届董事会第 15 次会 议通知于 2025 年 10 月 13 日以书面方式发出，会议于 2025 年 10 月 23 日下午 13:20 在公司会议室以现场会议方式召开，会议应到董事 15 人，实到 15 人，公司监事、 部分高管列席会议。会议符合《公司法》和《公司章程》的有关规定，会议合法、 有效。会议由公司董事长周辉女士主持，经与会人员逐项审议，通过了以下议案： 2025 年 10 月 25 日 1 表决情况为：有效表决票 15 票，其中：同意 15 票，反对 0 票，弃权 0 票。 天士力医药集团股份有限公司董事会 2、关于公司组织架构调整的议案 根据公司实际发展需要，为进一步增强组织效能、提升运营效率，对现行组 织架构进行调整。 1、2025 年第三季度报告 表决情况为：有效表 ...

Core Insights - The company reported a slight decline in revenue for the first three quarters of 2025, with total revenue at 1.007 billion yuan, a year-on-year decrease of 1.61% [1] - Net profit attributable to shareholders saw a significant increase of 119.05%, reaching 371 million yuan, indicating strong profitability growth [1] - Basic earnings per share improved to 1.44 yuan, reflecting a substantial increase compared to the same period last year [1] Financial Performance - The net profit growth of 119.05% was primarily driven by non-recurring gains and continuous optimization of core business operations [1] - Excluding non-recurring items, the net profit was 127 million yuan, marking a year-on-year increase of 19.21%, demonstrating stable profitability in core operations [1] - The company achieved a net profit of 343 million yuan in the first half of the year, a remarkable increase of 235.04%, with the third quarter net profit approximately 28 million yuan, continuing the strong growth trend [1] - Operating cash flow net amount was 125 million yuan, up 35.98% year-on-year, indicating improved operational efficiency and enhanced collection capabilities [1] Research and Development - Research and development investment exceeded 60 million yuan in the first three quarters, facilitating the approval of multiple generic drugs and consistency evaluation products, including Cefaclor sustained-release tablets and Voriconazole [2] - The company is deepening its "industry + capital" dual-drive strategy, with over 300 quality merger and acquisition projects in reserve to strengthen its industry chain layout [2] - Initiatives such as reshaping distribution channels and reclaiming core product general agency rights have been implemented to enhance market control [2]

天士力医药集团股份有限公司 2025 年第三季度报告 证券代码：600535 证券简称：天士力 天士力医药集团股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人蔡金勇先生、主管会计工作负责人魏洁女士及会计机构负责人（会计主管人员） 林勇志先生保证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一）主要会计数据和财务指标 1 / 16 单位：元 币种：人民币 项目 本报告期 本报告期比 上年同期增 减变动幅度 (%) 年初至报告期末 年初至报告期 末比上年同期 增减变动幅度 (%) 营业收入 2,022,464,001.07 -3.27 6,310,672,857.39 -2.35 利润总额 248,134,735.12 21.62 1,152,753,398.51 ...

Core Viewpoint - The company reported a decline in revenue for the third quarter while achieving an increase in net profit, indicating a potential shift in operational efficiency despite lower sales [1] Financial Performance - Q3 revenue was 2.022 billion, a year-on-year decrease of 3.27% [1] - Q3 net profit was 210 million, a year-on-year increase of 16.56% [1] - Year-to-date revenue for the first three quarters was 6.311 billion, a year-on-year decrease of 2.35% [1] - Year-to-date net profit for the first three quarters was 984 million, a year-on-year increase of 16.88% [1]

Core Insights - The Tianjin North Chao District is focusing on developing two key industries: intelligent equipment manufacturing and biomedicine, while also planning for emerging sectors such as intelligent computing power, low-altitude economy, and robotics [1][2] Economic Growth - In 2024, the economic output of North Chao District is expected to increase by 14 billion yuan compared to the end of the 13th Five-Year Plan, with per capita disposable income reaching 49,600 yuan, an increase of 18,000 yuan [2] - The district has attracted 340 foreign-invested enterprises, including 34 Fortune 500 companies, with significant investments from firms like Flanders and LG Electronics [2] Foreign Investment and Trade - During the 14th Five-Year Plan period, actual foreign investment reached 500 million USD, and the total import and export volume achieved an average double-digit growth annually [2] - Over the past five years, North Chao District has introduced 105 major projects from the capital, with a total investment of 33 billion yuan [2] Industrial Development - The intelligent manufacturing valley has been included as a key platform for industrial cooperation in the Beijing-Tianjin-Hebei region, with over 600 enterprises gathered [2][3] - The district has attracted 558 key projects with domestic investment exceeding 70 billion yuan, forming five hundred billion-level industrial chains in high-end equipment, new energy, and new materials [3] Biomedicine Sector - The biomedicine industry has established a complete industrial chain from research and development to manufacturing, packaging, logistics, and sales, with partnerships like Tianjin Tasly Pharmaceutical and China Resources Sanjiu [3] Technological Transformation - Jiangtian Big Data has transformed from a "steel giant" to a "digital pioneer," investing 12 billion yuan to build the Beijing-Tianjin computing power industrial park [3] - The industrial output value of regulated enterprises has surpassed 140 billion yuan, with an increase of over 30 billion yuan compared to the end of the 13th Five-Year Plan [3]

受深圳出台并购重组行动方案消息刺激，22日早盘深圳本地股大幅高开。截至记者发稿时，建科院、深 赛格、广田集团、深物业A、力合科创、深纺织A、特力A等10多只本地股涨停，深水规院大涨逾11%。 《方案》提出，力争到2027年底，并购重组市场量质齐升，累计完成并购项目超200单、交易总额超 1000亿元，落地一批行业示范案例。 在丰富拓展并购重组融资渠道方面，《方案》鼓励符合条件的企业综合运用现金、股份、定向可转债、 科创债券等方式实施并购重组，用好重组股份对价分期支付、配套募集资金储架发行等机制。鼓励银行 机构通过并购贷款、银团贷款、投贷联动等方式对企业市场化兼并重组给予信贷支持。 根据深圳证监局数据，自去年"并购六条"发布以来，截至今年6月，深圳上市公司公布并购重组预案215 笔，160笔重组事项披露交易金额，合计超过450亿元。 其中，既涉及国有控股上市公司，也有民营上市公司，既有同行业并购，也有围绕补链强链开展等类 型，不仅紧紧围绕公司主营业务和战略发展方向进行，也有助于促进产业协同和提高整体产业链竞争 力。 具体来看，今年3月底，华润三九斥资62亿元收购天士力医药集团28%股份的交易完成过户，天士力成 ...